About Generation Bio
Generation Bio is a company based in Cambridge (United States) founded in 2016 by Phillip Samayoa and Mark Angelino was acquired by XOMA Corporation in December 2025. Generation Bio has raised $236.47 million across 3 funding rounds from investors including Fidelity Investments, T. Rowe Price and Farallon Capital Management. The company has 115 employees as of December 31, 2024. Generation Bio offers products and services including ctLNP-siRNA. Generation Bio operates in a competitive market with competitors including Moderna, BridgeBio, Spark Therapeutics, Alnylam and ATAI, among others.
- Headquarter Cambridge, United States
- Employees 115 as on 31 Dec, 2024
- Founders Phillip Samayoa, Mark Angelino
- Stage Public
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Generation Bio Co.
-
Annual Revenue
$19.89 M (USD)236.92as on Dec 31, 2024
-
Net Profit
-$131.67 M (USD)-3.99as on Dec 31, 2024
-
EBITDA
-$73.41 M (USD)41.87as on Dec 31, 2024
-
Total Equity Funding
$236.47 M (USD)
in 3 rounds
-
Latest Funding Round
$111.47 M (USD), Series C
Jan 10, 2020
-
Investors
Fidelity Investments
& 10 more
-
Employee Count
115
as on Dec 31, 2024
-
Acquired by
XOMA Corporation
(Dec 15, 2025)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Generation Bio
Generation Bio is a publicly listed company on the NASDAQ with ticker symbol GBIO in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of Generation Bio
Generation Bio offers a comprehensive portfolio of products and services, including ctLNP-siRNA.
Delivers siRNA to T cells for treating autoimmune diseases
People of Generation Bio
Unlock access to complete
Unlock access to complete
Leadership Team
8 people
Advisor Team
5 people
Founder Team
1 people
Chair Team
1 people
Unlock access to complete
Funding Insights of Generation Bio
Generation Bio has successfully raised a total of $236.47M across 3 strategic funding rounds. The most recent funding activity was a Series C round of $111.47 million completed in January 2020. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Generation Bio
Generation Bio has secured backing from 11 investors, including institutional and venture fund investors. Prominent investors backing the company include Fidelity Investments, T. Rowe Price and Farallon Capital Management.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Venture capital firm investing in life science and biotechnology sectors
|
Locked | Locked | Locked | |
|
Multiple investment strategies are pursued by this hedge fund.
|
Locked | Locked | Locked | |
|
Long-term private equity investments in transformational opportunities are pursued.
|
Locked | Locked | Locked |
Investor details for Generation Bio
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Generation Bio
Investment portfolio details for Generation Bio
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Generation Bio
Detailed financials for Generation Bio
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Generation Bio Comparisons
Peer comparison for Generation Bio
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Generation Bio
Generation Bio operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Moderna, BridgeBio, Spark Therapeutics, Alnylam and ATAI, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
mRNA-based therapeutics for diseases including cancer and infections are developed.
|
|
| Locked | Locked | Locked |
Therapeutics for genetic diseases are developed through targeted interventions.
|
|
| Locked | Locked | Locked |
Gene therapies for rare diseases including retinal dystrophies are developed.
|
|
| Locked | Locked | Locked |
RNA interference-based therapeutics are developed for multiple disorders.
|
|
| Locked | Locked | Locked |
A biopharmaceutical company accelerating innovative mental health treatments.
|
|
| Locked | Locked | Locked |
An AI-enabled platform is developed for infectious disease treatment.
|
Detailed competitors of Generation Bio
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Generation Bio
Complete news archive for Generation Bio
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Generation Bio
Generation Bio was founded in 2016 and raised its 1st funding round 2 years after it was founded.
Generation Bio is headquartered in Cambridge, United States. It is registered at Cambridge, Massachusetts, United States.
Geoff McDonough is the current CEO of Generation Bio.
Generation Bio is a funded company, having raised a total of $236.47M across 3 funding rounds to date.
As of Dec 31, 2024, the latest employee count at Generation Bio is 115.
Annual revenue of Generation Bio is $19.89M as on Dec 31, 2024.
Generation Bio was founded in 2016 in Cambridge, United States, within the biotechnology sector. Non-viral gene therapies are provided for conditions such as phenylketonuria, hemophilia A, Wilson disease, Leber congenital amaurosis, and Stargardt disease. The Gene Wave technology enables optimal titration and re-dosing through closed-ended DNA. This ceDNA is packaged in lipid nanoparticles, which dissolve into cell cytoplasm and enter the nucleus to produce proteins.
Generation Bio's top competitors include Moderna, Spark Therapeutics and BridgeBio.
Generation Bio offers ctLNP-siRNA.
Yes, Generation Bio is publicly traded on NASDAQ under the ticker symbol GBIO.
Generation Bio has 11 investors. Key investors include Fidelity Investments, T. Rowe Price, Farallon Capital Management, Atlas Venture, and XOMA Corporation.
The ticker symbol of Generation Bio is GBIO on NASDAQ.